36078-54-3

Usage

Structure

Substituted benzene (a benzene ring with a butyl group and a chloromethyl group attached to it)

Usage

Precursor in organic synthesis (used as a starting material in chemical reactions to form other compounds) and production of various industrial and consumer products

Applications

Manufacture of pharmaceuticals, agrochemicals, and other specialty chemicals

Physical properties

Colorless liquid with a characteristic aromatic odor

Hazard classification

Hazardous substance (requires proper handling and disposal to minimize risks to human health and the environment)

Upstream product

• 50-00-0 formaldehyd 
• 104-51-8 1-butylbenzene 
• 1200-14-2 4-(n-butyl)benzaldehyde 
• 60834-63-1 p-butylbenzyl alcohol 
• 109-72-8 n-butyllithium 
• 589-17-3 p-bromobenzyl chloride 

Downstream Products

• 105872-07-9 (4-n-butylphenyl)acetonitrile 
• 1595-05-7 p-butyltoluene 
• 1200-14-2 4-(n-butyl)benzaldehyde 
• 38444-43-8 trans-4-butyl-4′-methoxystilbene 
• 49647-50-9 C₂₂H₃₀O₂S 
• 1209-19-4 3-(4'-butylphenyl)propanoic acid 
• 1216-20-2 ethyl 3-(4-butylphenyl)propanoate 
• 14377-19-6 [4-(n-Butyl)phenyl]acetic acid 
• 1027201-18-8 8-bromo-N²-butyl-9-(4-butyl-benzyl)-9H-purine-2,6-diamine 

Relevant academic research and scientific papers

Oxygen Activated, Palladium Nanoparticle Catalyzed, Ultrafast Cross-Coupling of Organolithium Reagents

The discovery of an ultrafast cross-coupling of alkyl- and aryllithium reagents with a range of aryl bromides is presented. The essential role of molecular oxygen to form the active palladium catalyst was established; palladium nanoparticles that are highly active in cross-coupling reactions with reaction times ranging from 5 s to 5 min are thus generated in situ. High selectivities were observed for a range of heterocycles and functional groups as well as for an expanded scope of organolithium reagents. The applicability of this method was showcased by the synthesis of the [11C]-labeled PET tracer celecoxib.

Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity

A series of N1-(4-substituted-benzyl)-pyrimidines were synthesized as potential inhibitors of thymidine monophosphate kinase of Mycobacterium tuberculosis (TMPKmt). Key SAR parameters included the chain length substitution in para position of t

Carboxilic acid derivatives

A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R1 represents a C6-10 ary

N-Phenyloxamide derivatives

A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R1 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, cyano group, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group and a C1-6 alkylsulfanyl group, R2 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, hydroxy group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group, a C1-6 alkylsulfanyl group and phenyl group, X represents a single bond or oxygen atom, Z represents a phenylene group or a substituted phenylene group, m represents 0 or 1.

FUNGAL CELL WALL SYNTHESIS GENE

A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed.Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.